On March 8, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported two poster presentations at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) virtual annual meeting taking place April 8-13, 2022 (Press release, Tempest Therapeutics, MAR 8, 2022, View Source [SID1234609664]). The presentations contain new preclinical data for two of Tempest’s small molecule programs, TPST-1495 (clinical-stage dual EP2/4 antagonist) and TREX1 (preclinical STING agonist).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details:

Title: Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway

Session Title: Inflammation, Tumor Intitiation and Progression
Session Date and Time: Monday April 11, 2022 9:00 a.m. – 12:30 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Abstract Number: 1333

Title: Systemic Small Molecule TREX1 Inhibitors to Selectively Activicate STING in the TME of Metastatic Disease

Session Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Monday April 11, 2022 1:30 p.m. – 5:00 p.m. CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Abstract Number: 2075

Full abstracts are available for viewing in the AACR (Free AACR Whitepaper) Online Itinerary Planner located here, View Source!/10517.